British Biotech Pharmaceuticals Limited

Christopher David Floyd

Mark Whittaker

Christopher Norman Lewis

Andrew Miller

Raymond Paul Beckett

Stephen Arthur Bowles

Lars Michael Wood

Sanjay Ratilal Patel

Compounds of formula (I), wherein A, B, X, R,, R,, R,, R,, R,, R,are as defined in the specification, are matrix metalloproteinase inhibitors.

Metalloproteinase inhibitors

The present invention describes processes for preparing desired synthetic products that comprise a covalently bonded hydroxamic acid group &mdash;CONHOH by forming a mixture of a liquid reaction medium and a solid phase reaction product that carries a plurality of moieties of formula (A1) or (B1):

Synthesis of hydroxamic acid derivatives

The present invention describes solid phase reaction products of a solid substrate carrying a plurality of covalently bound hydroxylamine or protected hydroxylamine groups of formula (A) or (B): ##STR1## where P.sub.1 is hydrogen or an amino protecting group, P.sub.2 is hydrogen or a hydroxyl protecting group, and the bond designated (a) covalently links the formula (A) or (B) to the residue of the solid substrate, and is cleavable under acid conditions or by photolysis. The solid phase reaction products can be used for the synthesis of hydroxamic acid derivatives or a combinatorial library of such compounds.

Synthesis of carboxylic and hydroxamic acid derivatives

Heterocyclic sulfonamide derivatives as antagonists of PAF and

Growing community of inventors

Oxford, United Kingdom

Christopher David Floyd